Candidate tumor markers related to the mechanism of action of PD-1 inhibitors, such as PD-L1 tissue expression, immune cell infiltrate and tumor mutation burden are not reliable predictors of a response to immunotherapy in melanoma [27,28]. This evidence concerns the gene CD274 and neoplasm.